ITGA4 polymorphisms and susceptibility to multiple sclerosis

Journal of Neuroimmunology

Volumn 189, Issue 1-2, 2007, Pages 151-157

  O'Doherty, Catherine ^a   Roos, Izaura M ^b   Antiguedad, Alfredo ^c   Aransay, Ana M ^d   Hillert, Jan ^b   Vandenbroeck, Koen ^a,d  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HOSPITAL DE BASURTO   (Spain)

^d CIC BIOGUNE   (Spain)

Author keywords

Genetic; Integrin; ITGA4; Multiple sclerosis; Natalizumab; Polymorphism

Indexed keywords

ALPHA4 INTEGRIN;

ALLELE; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MANTEL HAENSZEL TEST; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; SPAIN;

EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTEGRIN ALPHA4; MALE; MULTIPLE SCLEROSIS; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; SPAIN;

EID: 34548473593     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2007.07.006     Document Type: Article

References (21)

1. Barcellos L.F., Sawcer S., Ramsay P.P., Baranzini S.E., Thomson G., Briggs F., Cree B.C., Begovich A.B., Villoslada P., Montalban X., Uccelli A., Savettieri G., Lincoln R.R., DeLoa C., Haines J.L., Pericak-Vance M.A., Compston A., Hauser S.L., and Oksenberg J.R. Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis. Hum. Mol. Genet. 15 (2006) 2813-2824
2. Bennett J.L. Natalizumab and progressive multifocal leukoencephalopathy: migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurol. Res. 28 (2006) 291-298
3. Eikelenboom M.J., Killestein J., Izeboud T., Kalkers N.F., Baars P.A., van Lier R.A., Barkhof F., Uitdehaag B.M., and Polman C.H. Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. J. Neuroimmunol. 158 (2005) 222-230
4. Hafler D.A. Multiple sclerosis. J. Clin. Invest. 113 (2004) 788-794
5. Heymann G.A., Kiesewetter H., and Salama A. Frequencies of alpha4 A3061G variants and identification of three new variants of the human integrin alpha4-subunit. Mol. Immunol. 39 (2003) 855-860
6. Hong J., Zang Y.C., Hutton G., Rivera V.M., and Zhang J.Z. Gene expression profiling of relevant biomarkers for treatment evaluation in multiple sclerosis. J. Neuroimmunol. 152 (2004) 126-139
7. Iglesias A.H., Camelo S., Hwang D., Villanueva R., Stephanopoulos G., and Dangond F. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J. Neuroimmunol. 150 (2004) 163-177
8. Jensen J., Krakauer M., and Sellebjerg F. Cytokines and adhesion molecules in multiple sclerosis patients treated with interferon-beta1b. Cytokine 29 (2005) 24-30
9. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P., Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B.Y., and Wolinsky J.S. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann. Neurol. 50 (2001) 121-127
10. Miller D.H., Khan O.A., Sheremata W.A., Blumhardt L.D., Rice G.P., Libonati M.A., Willmer-Hulme A.J., Dalton C.M., Miszkiel K.A., O'Connor P.W., International Natalizumab Multiple Sclerosis Trial, and Group. A controlled trial of natalizumab for relapsing multiple sclerosis. N. Engl. J. Med. 348 (2003) 15-23
11. Muraro P.A., Liberati L., Bonanni L., Pantalone A., Caporale C.M., Iarlori C., De Luca G., Farina D., Lugaresi A., and Gambi D. Decreased integrin gene expression in patients with MS responding to interferon-beta treatment. J. Neuroimmunol. 150 (2004) 123-131
12. O'Connell J.R., and Weeks D.E. PedCheck: a program for identification of genotype incompatibilities in linkage analysis. Am. J. Hum. Genet. 63 (1998) 259-266
13. O'Connor P., Miller D., Riester K., Yang M., Panzara M., Dalton C., Miszkiel K., Khan O., Rice G., Sheremata W., International Natalizumab Trial, and G. Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis. Mult. Scler. 11 (2005) 568-572
14. O'Doherty C., Villoslada P., and Vandenbroeck K. Pharmacogenomics of type I interferon therapy: a survey of response modifying genes. Cytokine Growth Factor Rev. 18 (2007) 211-222
15. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., and Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. See comment. Ann. Neurol. 13 (1983) 227-231
16. Ransohoff R.M. Mechanisms of inflammation in MS tissue: adhesion molecules and chemokines. J. Neuroimmunol. 98 (1999) 57-68
17. Sawcer S., Ban M., Maranian M., Yeo T.W., Compston A., Kirby A., Daly M.J., De Jager P.L., Walsh E., Lander E.S., Rioux J.D., Hafler D.A., Ivinson A., Rimmler J., Gregory S.G., Schmidt S., Pericak-Vance M.A., Akesson E., Hillert J., Datta P., Oturai A., Ryder L.P., Harbo H.F., Spurkland A., Myhr K.M., Laaksonen M., Booth D., Heard R., Stewart G., Lincoln R., Barcellos L.F., Hauser S.L., Oksenberg J.R., Kenealy S.J., Haines J.L., International Multiple Sclerosis Genetics, and Consortium. A high-density screen for linkage in multiple sclerosis. Am. J. Hum. Genet. 77 (2005) 454-467
18. Skol A.D., Scott L.J., Abecasis G.R., and Boehnke M. Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies. Nat. Genet. 38 (2006) 209-213
19. Soilu-Hanninen M., Laaksonen M., Hanninen A., Eralinna J.P., and Panelius M. Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS. J. Neuroimmunol. 167 (2005) 175-182
20. Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4 (2005) 510-518
21. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., and Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 356 (1992) 63-66